24 May 2022
\n \n \n \nCOVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.
\n \n\n \n \n18 May 2022
\n \n \n \nThe collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.
\n \n\n \n \n29 January 2022
\n \n \n \nResearchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.
\n \n\n \n \n25 January 2022
\n \n \n \n\n \n \n5 January 2022
\n \n \n \nA publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.
\n \n\n \n \n16 December 2021
\n \n \n \nEileen is awarded funding for her research into the tumour microenvironment
\n \n\n \n \n26 November 2021
\n \n \n \nAnneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.
\n \n\n \n \n24 November 2021
\n \n \n \nOxford researchers will lead a \u00a32m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.
\n \n\n \n \n7 October 2021
\n \n \n \nA new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
\n \n\n \n \n16 August 2021
\n \n \n \n\n \n \n8 April 2021
\n \n \n \nInitial success leads to new award for Oxford researcher pushing forward new cancer-hunting radiotherapy despite lockdown.
\n \n\n \n \n17 February 2021
\n \n \n \nResults from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
\n \n\n \n \n11 February 2021
\n \n \n \n\n \n \n2 December 2020
\n \n \n \nEarly findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.
\n \n\n \n \n9 October 2020
\n \n \n \nA pathway designed to investigate individuals with non-specific but concerning symptoms of cancer wins the BMJ Awards 2020 Cancer Care Team of the Year.
\n \n\n \n \n20 August 2020
\n \n \n \nProf. Anne Kiltie and her team discuss their important work into the effects of radiosensitisation on ageing cancer patients with the CRUK Science Blog.
\n \n\n \n \n22 July 2020
\n \n \n \nUnderstanding the molecular subtype of a cancer is becoming an importance part of the diagnostic process as it helps a doctor better understand a patient\u2019s prognosis, determine the best course of action for treatment and helps researchers devise new, more-efficient, precision therapies.
\n \n\n \n \n8 July 2020
\n \n \n \nProfessor Nicola Sibson has been involved in the CNIO platform to compile a repository for brain metastasis cell lines.
\n \n\n \n \n4 June 2020
\n \n \n \nOne of our scientists, Dr Hannah Bolland, has become a virtual teacher, connecting school students with science.
\n \n\n \n \n23 April 2020
\n \n \n \nMany congratulations to Dr Mark Hill, who has become a Fellow of the Society for Radiological Protection (FSRP).
\n \n\n \n \n